Progyny Tops EPS Forecast, Eyes Growth
The fertility benefits manager reported strong results for the fourth quarter.
Progyny (NASDAQ:PGNY), a pioneer in fertility benefits management, released its earnings for the fourth quarter on Feb. 27. The standout points were its impressive revenue and adjusted earnings per share (EPS) results, both of which surpassed analysts' consensus predictions. Revenue reached $298.4 million, compared to an estimate of $277 million, while adjusted EPS of $0.42 far exceeded the expected $0.10. However, reasons for concern persist, among them the detrimental impact of losing a large client.
Source: Analysts' estimates for the quarter provided by FactSet.
Progyny is an industry leader in reproductive health and fertility benefits solutions that develops innovative plans to deliver comprehensive treatments with better outcomes. Its standout offering, the Smart Cycle, simplifies and enhances fertility treatment access for members. In recent times, Progyny has focused on expanding its client base and maintaining high satisfaction among its members. The business emphasizes a data-driven approach and integrated pharmacy benefits, catering to members with holistic support during their fertility journeys.
